Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
| ▸ | GLS | O94925 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10573582 | 0.90 | MTNR1A (0.63) | SIGMAR1GRM7MAPTMTNR1AMTNR1B | |
| SCHEMBL6488557 | 0.87 | SIGMAR1 (0.52) | SIGMAR1GRM7MAPTMTNR1AMTNR1B | |
| SCHEMBL6499176 | 0.83 | KMT2A (0.50) | SIGMAR1 | |
| SCHEMBL10576167 | 0.82 | SIGMAR1 (0.64) | SIGMAR1GLSSMN1; SMN2 | |
| SCHEMBL29765515 | 0.81 | SIGMAR1 (0.63) | SIGMAR1GLS | |
| SCHEMBL29765379 | 0.80 | SIGMAR1 (0.70) | SIGMAR1 | |
| SCHEMBL25198406 | 0.79 | SIGMAR1 (0.62) | SIGMAR1GLSCA1CA2CA5A | |
| SCHEMBL14654975 | 0.79 | SIGMAR1 (0.62) | SIGMAR1MAPTGLSSMN1; SMN2 | |
| SCHEMBL34468370 | 0.77 | SIGMAR1 (0.56) | SIGMAR1GLSCA1CA2CA5A | |
| SCHEMBL29765435 | 0.77 | SIGMAR1 (0.59) | SIGMAR1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SIGMAR1 792/4885GRM7 4045/4885MAPT 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.